{"id":1365,"date":"2026-03-22T15:00:00","date_gmt":"2026-03-22T15:00:00","guid":{"rendered":"https:\/\/lotilabs.com\/resources\/?p=1365"},"modified":"2026-09-08T21:29:30","modified_gmt":"2026-09-08T21:29:30","slug":"tesamorelin-peptide-ghrh-analogue-research-guide","status":"publish","type":"post","link":"https:\/\/lotilabs.com\/resources\/tesamorelin-peptide-ghrh-analogue-research-guide\/","title":{"rendered":"Tesamorelin Peptide: GHRH Analogue Research, Mechanism of Action &#038; Metabolic Studies"},"content":{"rendered":"<p><em>For laboratory and research use only. Not for human consumption.<\/em><\/p>\n<p>Here\u2019s a problem that frustrated endocrine researchers for decades: native growth hormone-releasing hormone breaks down in minutes. Literally minutes. That\u2019s why Theratechnologies Inc. in Montreal started tinkering with the molecule in the first place \u2014 and what they came up with was <a href=\"https:\/\/lotilabs.com\/product\/tesamorelin-10mg\/\">tesamorelin<\/a>, a 44-amino acid GHRH analogue with one clever tweak that changes everything.<\/p>\n<p>That tweak? A trans-3-hexenoic acid group bolted onto the N-terminal tyrosine. It sounds minor. It isn\u2019t. That single lipophilic modification makes the compound resist the very enzymes that destroy native GHRH, and it tightens binding at the pituitary receptor.<\/p>\n<div class=\"ez-toc-v2_0_83 counter-hierarchy ez-toc-counter ez-toc-light-blue ez-toc-container-direction\" id=\"ez-toc-container\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a aria-label=\"Toggle Table of Content\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" href=\"#\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg class=\"list-377408\" fill=\"none\" height=\"20px\" style=\"fill: #999;color:#999\" viewbox=\"0 0 24 24\" width=\"20px\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg baseprofile=\"tiny\" class=\"arrow-unsorted-368013\" height=\"10px\" style=\"fill: #999;color:#999\" version=\"1.2\" viewbox=\"0 0 24 24\" width=\"10px\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"><\/path><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class=\"ez-toc-list ez-toc-list-level-1\"><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/lotilabs.com\/resources\/tesamorelin-peptide-ghrh-analogue-research-guide\/#What_Is_Tesamorelin_Chemical_Identity_Structure\">What Is Tesamorelin? Chemical Identity &amp; Structure<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/lotilabs.com\/resources\/tesamorelin-peptide-ghrh-analogue-research-guide\/#Development_History\">Development History<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/lotilabs.com\/resources\/tesamorelin-peptide-ghrh-analogue-research-guide\/#Mechanism_of_Action_How_Tesamorelin_Triggers_GH_Release\">Mechanism of Action: How Tesamorelin Triggers GH Release<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/lotilabs.com\/resources\/tesamorelin-peptide-ghrh-analogue-research-guide\/#Published_Research_Findings\">Published Research Findings<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/lotilabs.com\/resources\/tesamorelin-peptide-ghrh-analogue-research-guide\/#Pharmacokinetics_What_Researchers_Need_to_Know\">Pharmacokinetics: What Researchers Need to Know<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/lotilabs.com\/resources\/tesamorelin-peptide-ghrh-analogue-research-guide\/#Tesamorelin_vs_Other_GHRH_Analogues\">Tesamorelin vs. Other GHRH Analogues<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/lotilabs.com\/resources\/tesamorelin-peptide-ghrh-analogue-research-guide\/#Safety_Profile_Research_Considerations\">Safety Profile &amp; Research Considerations<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/lotilabs.com\/resources\/tesamorelin-peptide-ghrh-analogue-research-guide\/#Regulatory_Status\">Regulatory Status<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/lotilabs.com\/resources\/tesamorelin-peptide-ghrh-analogue-research-guide\/#Product_Specifications\">Product Specifications<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/lotilabs.com\/resources\/tesamorelin-peptide-ghrh-analogue-research-guide\/#Where_Tesamorelin_Research_Is_Heading\">Where Tesamorelin Research Is Heading<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/lotilabs.com\/resources\/tesamorelin-peptide-ghrh-analogue-research-guide\/#Conclusion\">Conclusion<\/a><\/li><li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/lotilabs.com\/resources\/tesamorelin-peptide-ghrh-analogue-research-guide\/#References\">References<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Is_Tesamorelin_Chemical_Identity_Structure\"><\/span><span class=\"ez-toc-section\" id=\"What_Is_Tesamorelin_Chemical_Identity_Structure\"><\/span>What Is Tesamorelin? Chemical Identity &amp; Structure<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>It carries the full 44-amino acid sequence of human GHRH (1-44). Same building blocks. One critical addition at the front end.<\/p>\n<table>\n<thead>\n<tr><th>Property<\/th><th>Value<\/th><\/tr>\n<\/thead>\n<tbody>\n<tr><td>Compound Name<\/td><td>Tesamorelin (TH9507)<\/td><\/tr>\n<tr><td>Brand Name<\/td><td>Branded prescription formulation<\/td><\/tr>\n<tr><td>CAS Number<\/td><td>218949-48-5<\/td><\/tr>\n<tr><td>Molecular Formula<\/td><td>C<sub>221<\/sub>H<sub>366<\/sub>N<sub>72<\/sub>O<sub>67<\/sub>S<\/td><\/tr>\n<tr><td>Molecular Weight<\/td><td>5,135.86 Da<\/td><\/tr>\n<tr><td>Amino Acid Length<\/td><td>44 residues<\/td><\/tr>\n<tr><td>Classification<\/td><td>GHRH receptor agonist<\/td><\/tr>\n<tr><td>N-Terminal Modification<\/td><td>trans-3-Hexenoic acid<\/td><\/tr>\n<tr><td>PubChem CID<\/td><td>146681838<\/td><\/tr>\n<tr><td>Storage<\/td><td>2\u20138\u00b0C (lyophilized powder)<\/td><\/tr>\n<\/tbody>\n<\/table>\n<p>So why does that N-terminal modification matter so much? Two reasons. First, the trans-3-hexenoic acid group shields the peptide from DPP-IV and other aminopeptidases \u2014 the enzymes that shred native GHRH within minutes. Without the modification, endogenous GHRH (1-44) has a circulating half-life of maybe 5 to 7 minutes. That\u2019s it. Gone. (PMID: 16052083). Tesamorelin survives long enough to do real work.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Development_History\"><\/span><span class=\"ez-toc-section\" id=\"Development_History\"><\/span>Development History<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The compound started life as TH9507 \u2014 lab code, no brand name, just a promising molecule in Theratechnologies\u2019 pipeline. The goal was straightforward: build a GHRH analogue that doesn\u2019t fall apart the second it enters the bloodstream.<\/p>\n<p>They succeeded. After Phase 2 and Phase 3 trials looking at how tesamorelin affected visceral fat stores, the FDA approved it in November 2010 under a branded prescription name. The compound keeps showing up in new contexts.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Mechanism_of_Action_How_Tesamorelin_Triggers_GH_Release\"><\/span><span class=\"ez-toc-section\" id=\"Mechanism_of_Action_How_Tesamorelin_Triggers_GH_Release\"><\/span>Mechanism of Action: How Tesamorelin Triggers GH Release<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Big picture: tesamorelin binds the GHRH receptor on your pituitary. Done.<\/p>\n<h3>Pituitary GHRH Receptor Binding<\/h3>\n<p>Tesamorelin finds GHRH receptors on somatotroph cells sitting in the anterior pituitary and latches on. And here\u2019s the kicker \u2014 that trans-3-hexenoic acid mod creates a tighter grip than native GHRH manages. Stronger binding. Stronger activation.<\/p>\n<h3>The Signaling Chain<\/h3>\n<p>Receptor engagement sets off a domino run:<\/p>\n<ol>\n<li><strong>G<sub>\u03b1s<\/sub> protein flips on<\/strong> \u2014 activating adenylyl cyclase<\/li>\n<li><strong>cAMP floods in<\/strong> \u2014 adenylyl cyclase converts ATP to cyclic AMP, fast<\/li>\n<li><strong>PKA fires up<\/strong> \u2014 all that cAMP wakes protein kinase A<\/li>\n<li><strong>CREB gets tagged<\/strong> \u2014 phosphorylated, shipped to the nucleus<\/li>\n\n<li><strong>GH dumps into blood<\/strong> \u2014 simultaneously, PKA cracks open calcium channels and pre-formed GH granules pour out via exocytosis<\/li>\n<\/ol>\n<p>It preserves pulsatile release. Somatostatin still pumps the brakes between pulses. Feedback loops stay wired. You don\u2019t get a flat-line dump of exogenous hormone \u2014 you get the real pattern, the one your pituitary was designed to produce. If you\u2019re studying physiological GH secretion, this is a critical distinction. Not a minor footnote. Critical.<\/p>\n<h3>The IGF-1 Handoff<\/h3>\n<p>GH is actually a middleman. That falls on IGF-1. Researchers use IGF-1 elevation as their proof-of-concept marker for tesamorelin activity (PMID: 18057338). If IGF-1 isn\u2019t moving, the compound isn\u2019t working. Simple as that.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Published_Research_Findings\"><\/span><span class=\"ez-toc-section\" id=\"Published_Research_Findings\"><\/span>Published Research Findings<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This isn\u2019t a compound with a handful of pilot studies and some hand-waving. Tesamorelin has randomized controlled trial data. Multiple trials. Here\u2019s what they found.<\/p>\n<h3>Visceral Fat: The Big One<\/h3>\n<p>Falutz et al. pooled data from two multicenter, double-blind, placebo-controlled Phase 3 studies \u2014 816 subjects, 26 weeks (PMID: 23015655). The numbers were clear:<\/p>\n<ul>\n\n<li>Placebo groups: <strong>+5.0%<\/strong> \u2014 they gained visceral fat<\/li>\n<li>Between-group difference: P&lt;0.001<\/li>\n<li>Trunk fat dropped too<\/li>\n<\/ul>\n<p>A 20-point swing between drug and placebo. Different study, same story.<\/p>\n<h3>Liver Fat: This Is Where It Gets Really Interesting<\/h3>\n<p>Stanley et al. ran a 12-month randomized controlled study with 60 subjects who had excess abdominal adiposity (PMID: 24823457). What they found caught a lot of attention:<\/p>\n<ul>\n<li>Tesamorelin cut hepatic fat fraction by <strong>37%<\/strong> relative to baseline<\/li>\n<li>Placebo group? Their liver fat <strong>went up 27%<\/strong><\/li>\n<li>Absolute drop: \u22123.7 percentage points tesamorelin vs. +1.7 placebo<\/li>\n<li>More subjects in the tesamorelin arm met criteria for hepatic steatosis resolution<\/li>\n<\/ul>\n\n<p>This one snuck up on people.<\/p>\n<ul>\n\n<li>All while visceral fat was going down<\/li>\n<\/ul>\n<p>That caught the attention of sarcopenia researchers pretty quickly.<\/p>\n\n<p>This is newer and still developing.<\/p>\n\n<p>Published data also shows:<\/p>\n<ul>\n\n<li><strong>Adiponectin:<\/strong> Went up.<\/li>\n\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Pharmacokinetics_What_Researchers_Need_to_Know\"><\/span><span class=\"ez-toc-section\" id=\"Pharmacokinetics_What_Researchers_Need_to_Know\"><\/span>Pharmacokinetics: What Researchers Need to Know<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Numbers first:<\/p>\n<table>\n<thead>\n<tr><th>Parameter<\/th><th>Value<\/th><\/tr>\n<\/thead>\n<tbody>\n\n<tr><td>Bioavailability (SC)<\/td><td>~4% (typical for large peptides)<\/td><\/tr>\n<tr><td>T<sub>max<\/sub><\/td><td>~0.15 hours (~9 minutes)<\/td><\/tr>\n<tr><td>Half-life<\/td><td>26 min (tesamorelin); 38 min (GHRH 1-44 fragment)<\/td><\/tr>\n<tr><td>Peak GH Response<\/td><td><\/td><\/tr>\n<tr><td>IGF-1 Elevation<\/td><td>Sustained over weeks of administration<\/td><\/tr>\n<tr><td>Metabolism<\/td><td>Proteolytic cleavage to GHRH(1-44) and smaller fragments<\/td><\/tr>\n<tr><td>Protein Binding<\/td><\/tr>\n<\/tbody>\n<\/table>\n<p>Four percent bioavailability. That sounds terrible \u2014 and for a small molecule, it would be. But it\u2019s normal for large peptides. The thing to wrap your head around: tesamorelin itself is gone from plasma in about 26 minutes. But the GH pulse it triggers lasts 2 to 4 hours. So the compound disappears fast, but its biological footprint doesn\u2019t. That disconnect between pharmacokinetics and pharmacodynamics is something researchers absolutely must account for in protocol design (PMID: 36356032).<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Tesamorelin_vs_Other_GHRH_Analogues\"><\/span><span class=\"ez-toc-section\" id=\"Tesamorelin_vs_Other_GHRH_Analogues\"><\/span>Tesamorelin vs. Other GHRH Analogues<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>If you\u2019re running GH secretagogue experiments, you\u2019ve probably looked at <a href=\"https:\/\/lotilabs.com\/product\/sermorelin\/\">sermorelin<\/a>, <a href=\"https:\/\/lotilabs.com\/product\/cjc-1295-without-dac\/\">CJC-1295<\/a>, and tesamorelin side by side. Here\u2019s how they stack up:<\/p>\n<table>\n<thead>\n<tr><th>Property<\/th><th>Tesamorelin<\/th><th>Sermorelin<\/th><th>CJC-1295 (no DAC)<\/th><th>CJC-1295 (with DAC)<\/th><\/tr>\n<\/thead>\n<tbody>\n<tr><td>Amino Acids<\/td><td>44<\/td><td>29<\/td><td>29 (modified)<\/td><td>29 (modified)<\/td><\/tr>\n<tr><td>GHRH Sequence<\/td><td>Full GHRH(1-44)<\/td><td>GHRH(1-29)<\/td><td>Modified GHRH(1-29)<\/td><td>Modified GHRH(1-29)<\/td><\/tr>\n<tr><td>Key Modification<\/td><td>trans-3-hexenoic acid (N-term)<\/td><td>None (truncated native)<\/td><td>4 amino acid substitutions<\/td><td>4 substitutions + DAC<\/td><\/tr>\n<tr><td>Half-life<\/td><td>~26 min<\/td><td>~10\u201320 min<\/td><td>~30 min<\/td><td>~8 days<\/td><\/tr>\n<tr><td>GH Release Pattern<\/td><td>Pulsatile<\/td><td>Pulsatile<\/td><td>Pulsatile<\/td><td>Sustained\/blunted pulsatility<\/td><\/tr>\n<tr><td>DPP-IV Resistance<\/td><td>Minimal<\/td><td>High (amino acid subs)<\/td><td>High<\/td><\/tr>\n<tr><td>IGF-1 Elevation<\/td><td>Significant, sustained<\/td><td>Moderate<\/td><td>Moderate<\/td><td>Prolonged<\/td><\/tr>\n<tr><td>Visceral Fat Data<\/td><td>Extensive Phase 3 data<\/td><td>Limited<\/td><td>Limited<\/td><td>Limited<\/td><\/tr>\n<tr><td>Published Trials<\/td><td>Multiple Phase 2\/3 RCTs<\/td><td>Moderate<\/td><td>Limited<\/td><td>Limited<\/td><\/tr>\n<\/tbody>\n<\/table>\n<h3>Against Sermorelin<\/h3>\n<p><a href=\"https:\/\/lotilabs.com\/product\/sermorelin\/\">Sermorelin<\/a> is GHRH chopped to 29 amino acids. Still works \u2014 the truncated fragment keeps full receptor activity. Pulsatile release? Check. But there\u2019s no N-terminal shield. DPP-IV enzymes tear it apart.<\/p>\n<h3>Against CJC-1295<\/h3>\n<p>Different philosophy here. <a href=\"https:\/\/lotilabs.com\/product\/cjc-1295-without-dac\/\">CJC-1295 without DAC<\/a> \u2014 Mod GRF 1-29 if you prefer the other name \u2014 swaps out four amino acids at positions 2, 8, 15, and 27. Those substitutions block DPP-IV from cutting the chain. Half-life: about 30 minutes. Comparable to tesamorelin. Keeps pulsatile release intact. And it stacks well with ghrelin agonists like <a href=\"https:\/\/lotilabs.com\/product\/ipamorelin\/\">ipamorelin<\/a> \u2014 researchers like that combination for synergistic GH output.<\/p>\n<p>Then there\u2019s <a href=\"https:\/\/lotilabs.com\/product\/cjc1295-w-dac\/\">CJC-1295 with DAC<\/a>. Totally different beast. The Drug Affinity Complex grabs serum albumin and hangs on, pushing the half-life to around 8 days. Sounds ideal until you realize it might flatten the natural GH pulse pattern. If your experiments need physiological rhythm, that trade-off could be a deal-breaker.<\/p>\n<h3>Combo Approaches<\/h3>\n<p>Why pick one when you can push from both sides? Plenty of researchers pair GHRH agonists with ghrelin receptor agonists for synergistic GH release. Two different receptor systems, one combined output. The <a href=\"https:\/\/lotilabs.com\/product\/cjc-1295-no-dac-5mg-ipamorelin-5mg-blend\/\">CJC-1295\/Ipamorelin blend<\/a> is the classic pairing.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Safety_Profile_Research_Considerations\"><\/span><span class=\"ez-toc-section\" id=\"Safety_Profile_Research_Considerations\"><\/span>Safety Profile &amp; Research Considerations<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The pooled Phase 3 analysis (PMID: 23015655) gives a reasonably clear safety picture across hundreds of subjects:<\/p>\n<ul>\n<li><strong><\/strong> Most common finding.<\/li>\n<li><strong>IGF-1 went up:<\/strong> Consistently. But it dropped back to baseline when administration stopped. Reversible<\/li>\n<li><strong>Glucose:<\/strong> Some subgroups saw small fasting glucose increases, but HbA1c changes weren\u2019t statistically significant in most analyses<\/li>\n<li><strong>Fluid retention:<\/strong> Some peripheral edema and joint discomfort \u2014 expected with GH-mediated effects<\/li>\n<li><strong>Liver enzymes:<\/strong> ALT levels didn\u2019t differ between tesamorelin and placebo groups across studies. No acute liver injury cases reported (PMID: 18057338)<\/li>\n<\/ul>\n<p>Visceral fat reaccumulates after discontinuation. That\u2019s a real consideration for long-term study designs \u2014 and for interpreting what \u201csustained effect\u201d actually means with this compound.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Regulatory_Status\"><\/span><span class=\"ez-toc-section\" id=\"Regulatory_Status\"><\/span>Regulatory Status<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>FDA approved November 2010. Brand name: marketed as a branded prescription formulation (later reformulated in a single-vial format).<\/p>\n<p>For lab research, <a href=\"https:\/\/lotilabs.com\/product\/tesamorelin-10mg\/\">tesamorelin<\/a> is available as lyophilized powder at \u226598% purity, confirmed by third-party HPLC and mass spectrometry.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Product_Specifications\"><\/span><span class=\"ez-toc-section\" id=\"Product_Specifications\"><\/span>Product Specifications<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr><th>Specification<\/th><th>Details<\/th><\/tr>\n<\/thead>\n<tbody>\n<tr><td>Product<\/td><td><a href=\"https:\/\/lotilabs.com\/product\/tesamorelin-10mg\/\">Tesamorelin 10mg<\/a><\/td><\/tr>\n<tr><td>Form<\/td><td>Lyophilized powder<\/td><\/tr>\n<tr><td>Purity<\/td><td>\u226598% (HPLC verified)<\/td><\/tr>\n<tr><td>Third-Party Testing<\/td><td>Mass spectrometry + HPLC<\/td><\/tr>\n<tr><td>Storage<\/td><td>2\u20138\u00b0C, protect from light<\/td><\/tr>\n<tr><td>CAS Number<\/td><td>218949-48-5<\/td><\/tr>\n<\/tbody>\n<\/table>\n<p>Related compounds for GH axis research: <a href=\"https:\/\/lotilabs.com\/product\/sermorelin\/\">Sermorelin 2mg<\/a>, <a href=\"https:\/\/lotilabs.com\/product\/cjc-1295-without-dac\/\">CJC-1295 (Mod GRF 1-29) 2mg<\/a>, <a href=\"https:\/\/lotilabs.com\/product\/cjc1295-w-dac\/\">CJC-1295 with DAC 2mg<\/a>, <a href=\"https:\/\/lotilabs.com\/product\/cjc-1295-no-dac-5mg-ipamorelin-5mg-blend\/\">CJC-1295\/Ipamorelin Blend<\/a>, and <a href=\"https:\/\/lotilabs.com\/product\/ipamorelin\/\">Ipamorelin 2mg<\/a>.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Where_Tesamorelin_Research_Is_Heading\"><\/span><span class=\"ez-toc-section\" id=\"Where_Tesamorelin_Research_Is_Heading\"><\/span>Where Tesamorelin Research Is Heading<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The compound isn\u2019t sitting still. Multiple angles are being explored right now:<\/p>\n<p><strong>NAFLD<\/strong> is the big one. Stanley\u2019s liver fat work blew a door open, and now researchers want to know if those results hold across broader populations. Fatty liver disease affects tens of millions of people and treatment options are limited.<\/p>\n<p><strong>Cognition<\/strong> is the wild card. But we\u2019ll need the data before getting too excited.<\/p>\n<p><strong>Sarcopenia<\/strong> crept in through the back door.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span>Conclusion<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Tesamorelin is the GHRH analogue with the receipts. A 37% relative cut in liver fat. And a mechanism that keeps pulsatile GH secretion intact instead of flooding the system with exogenous hormone.<\/p>\n<p>Not many research peptides have this depth of controlled trial data behind them. <a href=\"https:\/\/lotilabs.com\/product\/tesamorelin-10mg\/\">Tesamorelin 10mg<\/a> is available in high-purity lyophilized form for laboratory research.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"References\"><\/span><span class=\"ez-toc-section\" id=\"References\"><\/span>References<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ol>\n<li>Falutz J, et al. <em>J Clin Endocrinol Metab<\/em>. 2007. PMID: 16052083<\/li>\n<li>Falutz J, et al. Multicenter study of tesamorelin for visceral adiposity. <em>J Acquir Immune Defic Syndr<\/em>. 2008. PMID: 18057338<\/li>\n<li>Falutz J, Mamputu JC, Potvin D, et al. Pooled analysis of two Phase 3 trials with safety extension data. <em>Clin Infect Dis<\/em>. 2012;54:1642-51. PMID: 23015655<\/li>\n<li>Stanley TL, et al. <em>J Clin Endocrinol Metab<\/em>. 2014. PMID: 24823457<\/li>\n<li>Adrian S, et al. <em>Clin Infect Dis<\/em>. 2019. PMC6766405<\/li>\n<li>NCT02572323. Phase II Trial of Tesamorelin for Cognition. ClinicalTrials.gov.<\/li>\n<\/ol>\n<p><em>For laboratory and research use only. Not for human consumption. This article is intended for educational and informational purposes for qualified researchers.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In-depth research guide on tesamorelin, a 44-amino acid GHRH analogue with enhanced stability. <\/p>\n","protected":false},"author":1,"featured_media":1380,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-1365","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-peptides"],"_links":{"self":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/1365","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/comments?post=1365"}],"version-history":[{"count":1,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/1365\/revisions"}],"predecessor-version":[{"id":2438,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/1365\/revisions\/2438"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/media\/1380"}],"wp:attachment":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/media?parent=1365"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/categories?post=1365"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/tags?post=1365"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}